ArticleESMO open2026
A prospective study for brain metastasis imaging screening in patients with advanced HER2-positive or triple-negative breast cancer.
Article in ESMO open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCurrent guidelines for advanced breast cancer do not recommend routine brain imaging in neurologically asymptomatic patients. Prospective clinical evidence on the effectiveness of screening for early detection of brain metastasis (BM) remains limited. We conducted a prospective cohort study to evaluate the utility of magnetic resonance imaging (MRI) screening in patients with advanced human epidermal growth factor receptor 2-positive (HER2+) or triple-negative breast cancer (TNBC). PATIENTS AND
methodsIn this single-arm, prospective study, screening brain MRI was carried out at diagnosis in asymptomatic patients with advanced HER2+ or TNBC. Patients without BM on baseline MRI were monitored for the development of neurologic symptoms. Follow-up brain MRI studies were carried out at the initiation of second- and third-line systemic therapy. The primary endpoint was the detection rate of BM on screening MRI.
resultsMRI detected asymptomatic BM in 11/112 (9.8%) patients at baseline; the cumulative detection rates increased to 17.0% and 19.6% by the initiation of second- and third-line therapy, respectively. Through this serial screening strategy, two-thirds of all BM cases (22/33) were identified at an asymptomatic stage. Patients with baseline metastatic involvement of three or more organ sites outside the central nervous system had an increased risk of BM (hazard ratio 3.38), and 38.5% of patients in this subgroup were diagnosed with BM by MRI screening. Stereotactic radiosurgery (66.7%) was the most common initial treatment for BM, and the median overall survival after BM diagnosis was 23.3 months.
conclusionsTwo-thirds of BM cases in patients with advanced HER2+ or TNBC were diagnosed at an asymptomatic stage in this prospective serial brain MRI screening program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.